Federal cannabis reform could ease long standing advertising restrictions, unlocking real growth opportunities across legal markets. Changes in federal posture may reshape how brands reach customers, build loyalty, and scale responsibly.

A cannabis business owner running for Congress signals a shift from outside advocacy to direct representation in federal policymaking. The move highlights the industry’s growing political maturity and push for practical reform.

Trump’s push to reschedule cannabis signals growing federal recognition of medical use and opens pathways for expanded research and clearer CBD oversight. While not full legalization, the move reflects momentum rather than restriction.

A proposed federal cannabis legalization commission signals that lawmakers are seeking a real national framework. While it does not mean immediate legalization, it marks continued forward movement in federal cannabis policy.

Industry leaders and reform advocates welcomed federal cannabis rescheduling as historic, while stressing that major issues remain unresolved. The response highlights both progress and the continued need for criminal justice and state federal alignment reforms.

Aurora Cannabis shares surged as federal rescheduling discussions renewed investor optimism. The rally highlights how regulatory expectations are currently the biggest driver in cannabis capital markets.

Cannabis stocks jumped as investors reacted to renewed federal policy discussions around marijuana reclassification. A move away from Schedule I could ease tax and banking barriers, creating major structural changes for the industry.

Rumors are growing in Washington that a second Trump administration may aggressively pursue federal cannabis rescheduling. If it happens, it would reshape banking, insurance, taxes, and interstate commerce — transforming the entire cannabis industry.

A new federal amendment will ban hemp-derived THC products exceeding 0.4 mg THC per container, effectively eliminating the intoxicating hemp category. The rule will reshape the $28 billion hemp-THC industry and force businesses to prepare for major operational changes.

Congress’s latest budget deal would restrict hemp-derived THC products while removing provisions allowing VA doctors to recommend medical marijuana. The move tightens federal hemp oversight and highlights how cannabis reform momentum is slowing at the national level.

Republican support for federal cannabis legalization has dropped from 55% to 40%, according to a new Gallup poll. The decline highlights growing political polarization around cannabis — and potential challenges for federal reform heading into 2026.